Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind’s US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines.
Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company focused on nature-derived psychedelic medicine. She joined Psyence in 2020 from the Center for Mind-Body Medicine, a Washington, D.C.-based non-profit, where she led public policy.
“We are thrilled to welcome Mary-Elizabeth Gifford to Clearmind Medicine,” said Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “Her unparalleled expertise in psychedelic policies and regulatory landscapes, and longstanding collaborations with leading government officials, policy makers and investors oriented to this space, will be instrumental in advancing our US partnerships and positioning Clearmind as a leader in ethical, patient-centered psychedelic therapeutics.”
Gifford, commented, “It’s an honor to join Clearmind Medicine, a psychedelic biopharma distinguished by its IP portfolio of 31 granted patents. With clinical trials underway at both Yale School of Medicine and Johns Hopkins University School of Medicine as well as Hadassah University Medical Center in Jerusalem, and its Scientific Advisory Board that includes faculty physicians from Harvard, Yale, and the University of Pennsylvania, Clearmind aims to set the industry standard for scientific rigor and integrity.” She continued, “I bring deep appreciation for the innovative Clearmind leadership team and for CEO Dr. Zuloff-Shani, whose entrepreneurial achievements at the intersection of medicine, commerce, and science to alleviate human suffering is inspiring.”
Gifford serves pro bono as chair of the non-profit Global Wellness Institute’s Psychedelics & Healing Initiative, whose honorary chair is Rick Doblin, founder of MAPS, the Multidisciplinary Association for Psychedelic Studies. A trusted voice for mental health and psychedelic medicine on Capitol Hill and elsewhere, she was named a “Psychedelic Titan,” one of “the psychedelic industry’s most influential and impactful individuals,” by the news site Microdose. Spirituality & Health Magazine describes Gifford as “the most quietly influential woman working in psychedelics today.”
In May of 2025, Gifford chaired the steering committee for the inaugural Federal Psychedelic Summit, held at the National Press Club in Washington. She addressed the topic of psychedelic business ethics and “Profit with Purpose” at Psychedelic Science 2025 in Denver. She is active with the Johns Hopkins Psychedelic Ethics group and is a member of the Institute of Medical Ethics. In July of 2025, Mary-Elizabeth became the sole biopharma executive selected to study alongside leading attorneys, physicians, researchers and government officials at Harvard Law School ‘s psychedelic policy and law immersion program. A graduate of Brown University, she also had a post-graduate year studying the History of Mind-Body Medicine at Harvard.
Sean Hocking
Source link